摘要: Targeted therapies have revolutionized cancer treatment. Unfortunately, their success is limited due to the development of drug resistance within tumor, which an evolutionary process. Understanding how evolves a prerequisite better targeted therapies. Resistance usually explained as response pressure imposed by Thus, understanding can and should be used in design treatment cancer. In this article, drug-resistance reviewed from standpoint. The concept apoptosis-induced compensatory proliferation (AICP) developed. It shown that AICP helps explain some phenomena are observed experimentally cancers. Finally, potential targets suggested light AICP.
core.ac.uk
impactjournals.com参考文章(79)
C Wallace, G B Pierce, Differentiation of malignant to benign cells. Cancer Research. ,vol. 31, pp. 127- 134 ,(1971)
John W. Pepper, Drugs that target pathogen public goods are robust against evolved drug resistance Evolutionary Applications. ,vol. 5, pp. 757- 761 ,(2012) , 10.1111/J.1752-4571.2012.00254.X
Michael W. Schmitt, Lawrence A. Loeb, Jesse J. Salk, The influence of subclonal resistance mutations on targeted cancer therapy Nature Reviews Clinical Oncology. ,vol. 13, pp. 335- 347 ,(2016) , 10.1038/NRCLINONC.2015.175
Jamshid S. Khorashad, Michael W. Deininger, Thomas O’Hare, New concepts for CML clonality Oncotarget. ,vol. 4, pp. 7- 8 ,(2013) , 10.18632/ONCOTARGET.882
Heiko Kuip, Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™) Therapeutics and Clinical Risk Management. ,vol. 4, pp. 163- 187 ,(2008) , 10.2147/TCRM.S1527
Antoine Buetti-Dinh, Igor V. Pivkin, Ran Friedman, S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases Molecular BioSystems. ,vol. 11, pp. 2247- 2254 ,(2015) , 10.1039/C5MB00302D
P. Nowell, The clonal evolution of tumor cell populations Science. ,vol. 194, pp. 23- 28 ,(1976) , 10.1126/SCIENCE.959840
Adam S Crystal, Alice T Shaw, Lecia V Sequist, Luc Friboulet, Matthew J Niederst, Elizabeth L Lockerman, Rosa L Frias, Justin F Gainor, Arnaud Amzallag, Patricia Greninger, Dana Lee, Anuj Kalsy, Maria Gomez-Caraballo, Leila Elamine, Emily Howe, Wooyoung Hur, Eugene Lifshits, Hayley E Robinson, Ryohei Katayama, Anthony C Faber, Mark M Awad, Sridhar Ramaswamy, Mari Mino-Kenudson, A John Iafrate, Cyril H Benes, Jeffrey A Engelman, None, Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science. ,vol. 346, pp. 1480- 1486 ,(2014) , 10.1126/SCIENCE.1254721
Takaaki Hato, Jun Yamanouchi, Tatsushiro Tamura, Norimasa Hojo, Yasunari Niiya, Masashi Kohno, Shiro Bando, Yoshihiro Yakushijin, Kiyonori Takada, Ikuya Sakai, Masaki Yasukawa, Shigeru Fujita, Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia International Journal of Hematology. ,vol. 80, pp. 62- 66 ,(2004) , 10.1532/IJH97.04033
M V Blagosklonny, Target for cancer therapy: proliferating cells or stem cells. Leukemia. ,vol. 20, pp. 385- 391 ,(2006) , 10.1038/SJ.LEU.2404075